Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Wave Life Sciences Ltd. (NASDAQ: WVE) closed at $4.85 in the last session, up 4.08% from day before closing price of $4.66. In other words, the price has increased by $4.08 from its previous closing price. On the day, 0.5 million shares were traded. WVE stock price reached its highest trading level at $4.93 during the session, while it also had its lowest trading level at $4.7.
Ratios:
We take a closer look at WVE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.26 and its Current Ratio is at 1.26. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.53.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on December 19, 2023, Upgraded its rating to Outperform and sets its target price to $12 from $5 previously.
On July 05, 2023, Raymond James started tracking the stock assigning a Outperform rating and target price of $7.
Jefferies Downgraded its Buy to Hold on May 24, 2023, whereas the target price for the stock was revised from $7 to $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 03 ’24 when Moran Kyle sold 15,630 shares for $6.17 per share. The transaction valued at 96,421 led to the insider holds 33,921 shares of the business.
RA CAPITAL MANAGEMENT, L.P. bought 1,000,000 shares of WVE for $5,000,000 on Dec 11 ’23. The Director now owns 19,202,009 shares after completing the transaction at $5.00 per share. On Dec 07 ’23, another insider, GSK plc, who serves as the 10% Owner of the company, bought 3,300,000 shares for $5.00 each. As a result, the insider paid 16,500,000 and bolstered with 13,983,761 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WVE now has a Market Capitalization of 593077376 and an Enterprise Value of 432719072. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.23 while its Price-to-Book (P/B) ratio in mrq is 14.58. Its current Enterprise Value per Revenue stands at 3.819 whereas that against EBITDA is -6.869.
Stock Price History:
The Beta on a monthly basis for WVE is -1.01, which has changed by 0.31793475 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, WVE has reached a high of $7.67, while it has fallen to a 52-week low of $3.15. The 50-Day Moving Average of the stock is -11.72%, while the 200-Day Moving Average is calculated to be -4.11%.
Shares Statistics:
According to the various share statistics, WVE traded on average about 890.51K shares per day over the past 3-months and 484610 shares per day over the past 10 days. A total of 119.16M shares are outstanding, with a floating share count of 96.36M. Insiders hold about 21.20% of the company’s shares, while institutions hold 74.60% stake in the company. Shares short for WVE as of 1713139200 were 3151130 with a Short Ratio of 3.54, compared to 1710460800 on 2996234. Therefore, it implies a Short% of Shares Outstanding of 3151130 and a Short% of Float of 4.65.
Earnings Estimates
The performance of Wave Life Sciences Ltd. (WVE) in the stock market is under the watchful eye of 5.0 analysts actively contributing to its current rating.On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.04 and a low estimate of -$0.34, while EPS last year was -$0.27. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.19 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$0.63 and -$1.32 for the fiscal current year, implying an average EPS of -$1.01. EPS for the following year is -$1.07, with 5.0 analysts recommending between -$0.87 and -$1.52.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $22.95M. It ranges from a high estimate of $39.67M to a low estimate of $10M. As of the current estimate, Wave Life Sciences Ltd.’s year-ago sales were $32.33MFor the next quarter, 6 analysts are estimating revenue of $19.61M. There is a high estimate of $25M for the next quarter, whereas the lowest estimate is $10M.
A total of 6 analysts have provided revenue estimates for WVE’s current fiscal year. The highest revenue estimate was $100M, while the lowest revenue estimate was $40M, resulting in an average revenue estimate of $76.38M. In the same quarter a year ago, actual revenue was $113.31MBased on 6 analysts’ estimates, the company’s revenue will be $52.83M in the next fiscal year. The high estimate is $98.36M and the low estimate is $6M.
